Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.48 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.45 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.45 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 3/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481354 | 0.84 | PTGS2 (0.52) | PTGS2CXCL8FTO | |
| SCHEMBL22481034 | 0.80 | PTGS2 (0.46) | PTGS2HSD17B13CXCL8MT-CO2FTO | |
| SCHEMBL30795667 | 0.70 | GPR52 (0.55) | MRGPRX4GPR52 | |
| SCHEMBL1578844 | 0.70 | GPR52 (0.55) | MRGPRX4GPR52 | |
| SCHEMBL13679149 | 0.70 | PTGS2 (0.58) | PTGS2CXCL8MT-CO2 | |
| SCHEMBL13143940 | 0.70 | PTGS2 (0.53) | PTGS2CXCL8MT-CO2 | |
| SCHEMBL10748316 | 0.70 | CRBN (0.56) | GPR52 | |
| SCHEMBL12529312 | 0.70 | ESRRG (0.61) | — | |
| SCHEMBL30794636 | 0.70 | MCL1 (0.43) | CXCL8 | |
| SCHEMBL449207 | 0.70 | MCL1 (0.43) | CXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308102-A1 | MODULATORS OF POTASSIUM ION AND TRPV1 CHANNELS AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308102-A1 | MODULATORS OF POTASSIUM ION AND TRPV1 CHANNELS AND USES THEREOF | TRPV1, TRPV2, TRPV5 | PTGS2 573/4885HSD17B13 4329/4885CXCL8 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.